嗜铬细胞瘤合并甲状腺乳头状癌（附1例报告）

doi:10.16139/j.1007-9610.2023.02.14

摘要/Abstract

摘要：

嗜铬细胞瘤是一种少见的神经内分泌肿瘤，大多散发，约1/3为遗传性基因突变引起。甲状腺乳头状癌来源于甲状腺滤泡细胞，是最常见的恶性肿瘤。然而，嗜铬细胞瘤合并甲状腺乳头状癌的相关报道很少。我院一例41岁男性肾上腺嗜铬细胞瘤合并甲状腺乳头状癌。病人因细针穿刺诊断为甲状腺乳头状癌而入院手术。由于手术当天血压异常升高而手术暂停。行进一步血生化及CT检查，结果考虑可能合并肾上腺嗜铬细胞瘤。经多学科讨论，决定先行肾上腺手术，恢复后再行甲状腺癌根治术。嗜铬细胞瘤和甲状腺乳头状癌的同时存在究竟是一种巧合还是RET基因或未知的遗传基因突变引起，目前尚不清楚。需要积累这种组合病例以及基因检测，作进一步研究。

关键词: 甲状腺乳头状癌, 嗜铬细胞瘤, 神经内分泌肿瘤

Abstract:

Pheochromocytoma is one of rare tumors of neuroendocrine. Most of the tumors are sporadic with about 1/3 of them caused by genetic mutations. Papillary thyroid carcinoma (PTC) from thyroid follicular cells is the most common malignant tumors. However, pheochromocytoma with PTC is rarely reported. Here we present a case report of an 41-year-old male patient found to have an adrenal pheochromocytoma combined with PTC, and PTC was diagnosed first with fine needle aspiration. The patient admitted to hospital, and surgery would be prepared when abnormal blood pressure rose, and operation was suspended. Further CT scan and blood biochemical examination were performed, and concurrent adrenal pheochromocytoma was considered. Multidisciplinary team decided to perform adrenal surgery priority. When the recovery of patient appeared after first operation, radical thyroidectomy was performed. Whether the co-existence of pheochromocytoma and PTC is coincidence or caused by RET gene or unknown inherited genetic mutations is unclear, so accumulation of studies with more combined cases should be done and genetic testing data are needed.

Key words: Papillary thyroid carcinoma, Pheochromocytoma, Neuroendocrine neoplasm

中图分类号:

孔韦奇, 何俊, 杨成广, 刘微薇, 徐英杰. 嗜铬细胞瘤合并甲状腺乳头状癌（附1例报告）[J]. 外科理论与实践, 2023, 28(02): 162-165.

KONG Weiqi, HE Jun, YANG Chengguang, LIU Weiwei, XU Yingjie. Pheochromocytoma with papillary thyroid carcinoma: one case report[J]. Journal of Surgery Concepts & Practice, 2023, 28(02): 162-165.

图/表 4

参考文献 18

[1]	TAUJAN G C, BALEANU F, SPINATO L, et al. Multiple endocrine neoplasia or accidental association?[J]. Eur J Case Rep Intern Med, 2020, 7(11):001818.
[2]	MATHIESEN J S, EFFRAIMIDIS G, ROSSING M, et al. Multiple endocrine neoplasia type 2: a review[J]. Semin Cancer Biol, 2022, 79:163-179. doi: 10.1016/j.semcancer.2021.03.035 URL
[3]	ERLIC Z, RYBICKI L, PECZKOWSKA M, et al. Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients[J]. Clin Cancer Res, 2009, 15(20):6378-6385. doi: 10.1158/1078-0432.CCR-09-1237 pmid: 19825962
[4]	RASQUIN L, PRATER J, MAYRIN J, et al. Simulta-neous pheochromocytoma, paraganglioma, and papillary thyroid carcinoma without known mutation[J]. Case Rep Endocrinol, 2018, 2018:6358485.
[5]	YANG J H, BAE S J, PARK S, et al. Bilateral pheochromocytoma associated with paraganglioma and papillary thyroid carcinoma: report of an unusual case[J]. Endocr J, 2007, 54(2):227-231. doi: 10.1507/endocrj.k06-068 pmid: 17264467
[6]	NASSER T, QARI F. Pheochromocytoma, papillary thyroid carcinoma[J]. Saudi Med J, 2009, 30(8):1087-1090. pmid: 19668893
[7]	SISSON J C, GIORDANO T J, AVRAM A M. Three endocrine neoplasms: an unusual combination of pheochromocytoma, pituitary adenoma, and papillary thyroid carcinoma[J]. Thyroid, 2012, 22(4):430-436. doi: 10.1089/thy.2011.0345 pmid: 22385288
[8]	BECK O, FASSBENDER W J, BEYER P, et al. Pheochromocytoma in childhood: implication for further diagnostic procedures[J]. Acta Paediatr, 2004, 93(12):1630-1634. pmid: 15841772
[9]	BUGALHO M J, SILVA A L, DOMINGUES R. Coexistence of paraganglioma/pheochromocytoma and papillary thyroid carcinoma: a four-case series analysis[J]. Fam Cancer, 2015, 14(4):603-607. doi: 10.1007/s10689-015-9818-8 pmid: 26071763
[10]	WELLS S A Jr, ASA S L, DRALLE H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma[J]. Thyroid, 2015, 25(6):567-610. doi: 10.1089/thy.2014.0335 pmid: 25810047
[11]	LI S Y, DING Y Q, SI Y L, et al. 5P strategies for ma-nagement of multiple endocrine neoplasia type 2: a paradigm of precision medicine[J]. Front Endocrinol (Lausanne), 2020, 11:543246. doi: 10.3389/fendo.2020.543246 URL
[12]	FASSNACHT M, KREISSL M C, WEISMANN D, et al. New targets and therapeutic approaches for endocrine malignancies[J]. Pharmacol Ther, 2009, 123(1):117-141. doi: 10.1016/j.pharmthera.2009.03.013 URL
[13]	RAMONE T, ROMEI C, CIAMPI R, et al. Differential expression of RET isoforms in normal thyroid tissues, papillary and medullary thyroid carcinomas[J]. Endocrine, 2019, 65(3):623-629. doi: 10.1007/s12020-019-01957-2 pmid: 31278686
[14]	BALOH R H, ENOMOTO H, JOHNSON E M Jr, et al. The GDNF family ligands and receptors-implications for neural development[J]. Curr Opin Neurobiol, 2000, 10(1):103-110. doi: 10.1016/S0959-4388(99)00048-3 URL
[15]	SALVATORE D, SANTORO M, SCHLUMBERGER M. The importance of the RET gene in thyroid cancer and therapeutic implications[J]. Nat Rev Endocrinol, 2021, 17(5):296-306. doi: 10.1038/s41574-021-00470-9
[16]	REDAELLI S, PLAZA-MENACHO I, MOLOGNI L. Novel targeted therapeutics for MEN2[J]. Endocr Relat Cancer, 2018, 25(2):T53-T68. doi: 10.1530/ERC-17-0297 URL
[17]	KJELLMAN P, LEAROYD D L, MESSINA M, et al. Expression of the RET proto-oncogene in papillary thyroid carcinoma and its correlation with clinical outcome[J]. Br J Surg, 2001, 88(4):557-563. doi: 10.1046/j.1365-2168.2001.01734.x URL
[18]	INABA M, UMEMURA S, SATOH H, et al. Expression of RET in follicular cell-derived tumors of the thyroid gland: prevalence and implication of morphological type[J]. Pathol Int, 2003, 53(3):146-153. doi: 10.1046/j.1440-1827.2003.01447.x URL